Lymphology最新文献

Diagnosis and evaluation of genital lymphedema (GL) is a challenging yet crucial step in the treatment of GL. Single photon emission computed tomography-computed tomography (SPECT-CT) is useful for lymph flow imaging, but its characteristic findings for GL are not clarified. The purpose of this study was to uncover characteristic SPECT-CT findings in secondary GL. Medical records of patients who underwent SPECT-CT and indocyanine (ICG) lymphography for evaluation of secondary lower extremity lymphedema (LEL) and/or genital lymphedema (GL) were reviewed. Characteristic SPECT-CT findings were identified based on timing, visibility, and extension of lymphatic enhancement in the lower abdominal, inguinal, genital, and pelvic regions. Patients were divided into either GL group with genital ICG lymphography stage I-V or control group with stage 0. Prevalence of each SPECT-CT finding was compared between the groups. Ten female patients were included; 7 (70%) were classified in GL group, and 3 (30%) in control group. Characteristic SPECT-CT findings included pauci-enhancement of inguinal lymph nodes (PEIL), genital dermal back flow, external iliac lymph nodes non-enhancement, common iliac lymph nodes non-enhancement, and periaortic lymph nodes non-enhancement. There was a statistically significant difference between GL and control groups for PEIL (100% vs. 0%, P = 0.002). Characteristic SPECT-CT findings in secondary GL were identified. Further studies are warranted to clarify usefulness of the findings for management of GL.

The brain's lymphatic system is comprised of a glymphatic-meningeal-cervical lymphatic vessel pathway. The study of its mechanism and pathophysiology in neurodegenerative disease has been one of the most exciting topics in basic and translational neuroscience of the last decade. However, while there has been some debate about when the meningeal lymphatics were discovered, it cannot be denied that studies in preclinical models and humans in this century represent a monumental step forward in our understanding of how the brain removes metabolic waste, the role this system plays in neurodegenerative disease, and, most importantly, its potential as a novel therapeutic target. This is a summary of the history, functional anatomy, and role of the brain's lymphatics in neurodegenerative disease.

Author's response to letter concerning article: Witt, M, A Ring: Handley's Thread Lymphangioplasty Vs. BioBridge^TM Collagen Matrix for Lymphedema Therapy-Old Wine in New Bottles? Lymphology 56 (2023) 110-120.

Non-contrast magnetic resonance lymphography (NMRL) has been reported to be efficient for the evaluation of lymphedema. However, its characteristic findings and grading system are yet fully clarified. We retrospectively examined 48 patients with secondary lower extremity lymphedema (LEL) who underwent NMRL and indocyanine green lymphography (ICG-L). The lower extremity was divided into 5 areas for NMRL evaluation, and the prevalence of characteristic NMRL findings (Mist, Spray, and Inky) and the 3D NMRL stage that we proposed were compared according to the ICG-L stage. All characteristic NMRL findings increased in prevalence with the progression of the ICG-L stage (Mist, Spray, and Inky: P < 0.001, < 0.001, and < 0.001, respectively) Pre-dominant findings in each segment changed significantly from Mist in the ICG-L stage 0-Ⅱ, to the Spray in ICG-L stage Ⅲ-Ⅳ, to the Inky in ICG-L stage Ⅴ (P < 0.001). 3D NMRL stage significantly advanced with the progression of the ICG-L stage (rs = 0.72; P < 0.001). We believe this severity grading system is useful for efficient evaluation of fluid accumulation in LEL patients.

Access to trained lymphedema care providers remains limited making patient-driven management solutions essential. One such option, sequential intermittent pneumatic compression (IPC), has gained traction as a supportive tool for lymphedema management. While newer IPC devices and innovative applications are being introduced to the market, questions regarding the safety and efficacy of this technology persist. This underscores the importance of reviewing current literature to understand IPC's evolving role in lymphedema care and to identify existing knowledge gaps. A scoping review of literature was conducted across various databases using PRISMA-ScR guidelines. The eligibility criteria included articles published in English language from database's inception to June 2023, discussing IPC's safety, and/or efficacy, and/or optimal modes and settings for lymphedema management. Review articles and case reports and original studies with unclear outcome measures were excluded. The review identified 49 eligible studies from an initial pool of 614 articles, consisting of 12 randomized controlled trials, 25 cohort studies, and 12 experimental studies. Most studies (44) focused on limb lymphedema, while five examined non-limb regions. Sample sizes varied widely, ranging from 10 to 718 participants, reflecting differences in studies' power. Minor adverse events were reported in six studies, including transient skin irritation, paresthesia, and rare cases of genital edema. Efficacy data indicated that IPC, whether used with or without manual lymphatic drainage (MLD), improved limb volume, quality of life, and reduced infection rates, although results varied according to treatment protocols and limb type. The addition of IPC improved compliance of decongestive therapy and increased patient satisfaction. IPC sessions ranged from 45 to 120 minutes per day, conducted 3 to 7 days per week, with pressures set at 60 to 120 mmHg for lower limbs and 25 to 60 mmHg for upper limbs. Higher pressures were associated with more significant limb volume reduction in the lower limbs. A cost analysis indicated that IPC could potentially lead to healthcare savings by reducing infections and hospital admissions. IPC application also showed promising results in head and neck lymphedema, though results for trunk lymphedema were equivocal. Future research should aim to refine IPC protocols in different regions of the body and ascertain its long-term benefits.

We are sad to report the passing but will commemorate here the life and accomplishments of Alejandro Latorre Parra, MD, formerly Professor of the Medicine program at the Autonomous University of Bucaramanga - UNAB Faculty of Health Sciences and Director of the Escuela Colombiana de Linfologia.

Lipedema is usually thought of as a dis-ease of women. Potentially diagnostic comparative data is needed between patients with lip-edema and those with lower limb lymphedema (LLL). Since there is no gold standard to diagnose lipedema, some promising modalities such as Tissue Dielectric Constant (TDC) need to be investigated among patients with lipedema and lymphedema. This study was completed with a total of 26 patients (14 lipedema, 12 LLL). Local tissue water was assessed with Moisture MeterD compact (DelfinTech, Kuopio, Finland) according to the TDC method at 300 MHz within a 2.5 mm tissue penetration depth via the following reference points: Thigh, calf (20 cm upper and lower point of knee level, respectively), and malleoli (5 cm upper point of medial malleolus). Patients with LLL showed significantly higher TDC values and interlimb TDC ratios in all affected points and unaffected malleolus points compared to patients with lipedema. No significant difference was achieved between genders with LLL in all reference points. The area under the curve (AUC) for thigh, calf, and malleolus reference points were found as 0.851 (95%CI .678-1.00), 0.801 (95% CI 0.612-0.989) and 0.786 (95%CI 0.596-0.976), respectively. Patients with LLL showed significantly higher TDC values compared to patients with lipedema, these differences should be carefully interpreted in patients with bilateral LLL and those with lipo-lymphedema.

We are sad to report the passing but will commemorate here the life and accomplishments of Hugo Partsch, MD, formerly Professor of Dermatology at the University of Vienna and Head of the Dermatological De-partment at the Wilhelminen Hospital in Vienna.

Winning a scientific prize is always a welcome honor and receiving the Aselli Award in 2023 was a particularly pleasant surprise. The following text provides a brief summary of the research carried out by my group in Oxford that led to the discovery of the lymphatic endo-thelial marker LYVE-1 and its emerging role as a pivotal receptor controlling the entry of immune cells and metastatic tumor cells to lymphatic capillaries in peripheral tissues. As a basic scientist and relatively late comer to the field of lymphology, my hope is that a closer partnership of basic and clinical research will help explain the intricate workings of the lymphatics and improve the picture for patients suffering from much neglected lymphatic disorders.